Welcome to the Lilly Scientific Information Page for AAAAI 2026
American Academy of Allergy, Asthma & Immunology 2026
Philadelphia, PA
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support.
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X.
To receive the latest science and innovation, please be sure to follow us on LinkedIn.
Disclosures
FRIDAY
- Disease State: Atopic Dermatitis
- Presented by: Bob Geng
- Molecule(s): Lebrikizumab
Advancing Atopic Dermatitis Remission Criteria With Lebrikizumab Results in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Trial(s) Overview:
Not Applicable
FRIDAY
- Disease State: Atopic Dermatitis
- Presented by: Ujwala Kaza
- Molecule(s): Lebrikizumab
Lebrikizumab Clears Face Lesions in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis
Trial(s) Overview:
Not Applicable
FRIDAY
- Disease State: Atopic Dermatitis
- Presented by: Ujwala Kaza
- Molecule(s): Lebrikizumab
Lebrikizumab Improves Post-inflammatory Pigmentation in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Trial(s) Overview:
Not Applicable
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)